Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
11:05am, Monday, 27'th Apr 2026
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN?
09:30am, Monday, 27'th Apr 2026
From fees to fund size, subtle differences between ISCV and IWN may impact your approach to small-cap value investing.
CureVac sues Moderna for patent infringement over COVID-19 vaccines
04:52pm, Friday, 24'th Apr 2026
German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to messenger RNA (mRNA) techn
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Friday, 24'th Apr 2026
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
06:51pm, Wednesday, 22'nd Apr 2026
In the most recent trading session, Moderna (MRNA) closed at $55.6, indicating a +2.53% shift from the previous trading day.
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
12:15pm, Wednesday, 22'nd Apr 2026
Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
Moderna starts late-stage trial of bird flu vaccine in US, UK
07:13pm, Tuesday, 21'st Apr 2026
Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the U.S. and the UK, marking the first time a pandemic bird flu vaccine made with mRNA technolog
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
07:01pm, Tuesday, 21'st Apr 2026
Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April 2
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
10:00am, Tuesday, 21'st Apr 2026
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on it
Moderna wins EU approval for combined flu, COVID shot for older adults
09:59am, Tuesday, 21'st Apr 2026
Moderna said on Tuesday the European Commission had granted marketing authorization for a combination vaccine for the prevention of influenza and COVID-19 in adults 50
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, sub
Moderna to Present at Upcoming Conferences in May 2026
07:00am, Tuesday, 21'st Apr 2026
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: BofA Securities 2026 Healthcare Confer
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TP
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
06:50pm, Wednesday, 15'th Apr 2026
Moderna (MRNA) closed the most recent trading day at $54.26, moving +2.69% from the previous trading session.
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
07:00am, Wednesday, 15'th Apr 2026
CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its
